GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy

Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...

GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer

Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...
TMCnet

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

Mycosis fungoides, the most prevalent CTCL subtype, accounts for the majority of cases. Although early-stage disease has a five-year survival rate of roughly 88%, it is a chronic cancer with ...
BioSpace

FDA Probing Patient Death Linked to Takeda’s Enzyme Replacement Therapy

The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the protein the therapy replaces. The FDA is investigating adverse events, ...